Skip to content

Tim Schäfer

Pharmaceutical Microbiology, Friedrich Schiller University, Beutenbergstrasse 11a, Jena, Germany.

7 papers in the library · 93 citations · publishing 2022-2025

Papers

Genetic Survey of Psilocybe Natural Products

ChemBioChem May 18, 2022 Sebastian Dörner, Kai Rogge, Janis Fricke et al. 43 citations

Psilocybe magic mushrooms are best known for producing psilocybin and psilocin, but their broader secondary metabolome is poorly understood. Genomes of five species (P. azurescens, P. cubensis, P. cyanescens, P. mexicana, and P. serbica) revealed much greater and unexplored metabolic diversity than chemical analyses alone. P. cyanescens and P. mexicana were identified as aeruginascin producers. Lumichrome and verpacamide A were also detected as Psilocybe metabolites. These findings support efforts to understand phenomena like paralytic effects attributed to some magic mushrooms.

Characterization of the Gateway Decarboxylase for Psilocybin Biosynthesis

ChemBioChem November 3, 2022 Tim Schäfer, Kristina Kramer, Sebastiaan Werten et al. 20 citations

The enzyme PsiD from the mushroom Psilocybe cubensis initiates the production of psilocybin, the psychedelic compound in magic mushrooms that is being investigated as a treatment for major depressive disorder. Unlike most similar enzymes, PsiD does not require pyridoxal phosphate (PLP) and instead resembles type II phosphatidylserine decarboxylases. Through biochemical experiments and computer modeling, researchers identified and confirmed a non-standard serine protease triad that enables the enzyme to cleave itself into its active form. This finding clarifies the molecular mechanism behind the first step of psilocybin biosynthesis.

Optimized psilocybin production in tryptophan catabolism‐repressed fungi

Microbial Biotechnology November 1, 2024 Slavica Janevska, Sophie Weiser, Ying Huang et al. 13 citations

By deleting genes involved in L-tryptophan catabolism, psilocybin production was increased fivefold in baker's yeast and tenfold in the filamentous fungus Aspergillus nidulans. Process optimization in A. nidulans batch cultures yielded a final psilocybin titre of 267 mg/L with a space-time-yield of 3.7 mg/L/h. The engineered strain demonstrates suitability as a production chassis for psilocybin and other tryptamine-derived pharmaceuticals.

Genetic regulation of L-tryptophan metabolism in Psilocybe mexicana supports psilocybin biosynthesis.

Fungal biology and biotechnology April 25, 2024 Paula Sophie Seibold, Sebastian Dörner, Janis Fricke et al. 8 citations

Psilocybin, a psychedelic alkaloid, can account for up to 2% of the dry mass of Psilocybe mushrooms, creating a high demand for its precursor L-tryptophan during carpophore (fruiting body) formation. Using Psilocybe mexicana, researchers found that genes for L-tryptophan biosynthesis (trpE1, trpD, trpB) were upregulated in carpophores, while genes for L-tryptophan-consuming pathways (idoA, iasA) were massively downregulated. The IasA enzyme was characterized as the first microbial L-tryptophan-preferring acetaldehyde synthase. Comparison with Psilocybe cubensis revealed species-specific differences in regulation. This coordination of primary and secondary metabolism routes L-tryptophan toward psilocybin production, providing initial insight into how Basidiomycota manage metabolic flux.

Dissimilar Reactions and Enzymes for Psilocybin Biosynthesis in Inocybe and Psilocybe Mushrooms

Angewandte Chemie International Edition September 21, 2025 Tim Schäfer, Fabian Haun, Bernhard Rupp et al. 7 citations

Psilocybin, the main psychoactive compound in magic mushrooms, is also produced by some Inocybe species. Researchers characterized four enzymes from Inocybe corydalina and found that none of the reactions used in Psilocybe species occur in this species. Instead, the Inocybe pathway is branched and produces baeocystin as a second end product. These results show that mushrooms evolved the ability to make psilocybin twice independently, using distantly related or entirely different enzymes.

In Vitro Psilocybin Synthesis by Co‐Immobilized Enzymes

Chemistry - A European Journal April 9, 2025 Tim Schäfer, Thomas Krüger, Jakob Worbs et al. 2 citations

A reusable solid-phase resin coated with five enzymes—three from Psilocybe mushrooms and two from E. coli—converts 4-hydroxy-L-tryptophan into psilocybin quantitatively in a proof-of-principle in vitro experiment. This biocatalytic approach offers a sustainable, selective alternative to synthetic production for the drug candidate being tested in advanced clinical trials for major depressive disorder.

Unterschiedliche Reaktionen und Enzyme in der Psilocybin‐ Biosynthese bei Inocybe‐ und Psilocybe ‐Pilzen

Angewandte Chemie September 21, 2025 Tim Schäfer, Fabian Haun, Bernhard Rupp et al.

Psilocybin, the main psychoactive alkaloid in magic mushrooms, is produced by several fungal genera. In Psilocybe species the biosynthetic pathway from L-tryptophan is well characterized. This work examined the pathway in Inocybe corydalina, a distantly related mushroom that also makes psilocybin. Four recombinant enzymes from I. corydalina were characterized in vitro: a decarboxylase (IpsD), a kinase (IpsK), and two methyltransferases (IpsM1 and IpsM2); a fifth monooxygenase (IpsH) was analyzed in silico. None of the reactions matched those in Psilocybe. The Inocybe pathway is branched and also produces baeocystin as a second end product. The findings indicate that psilocybin biosynthesis evolved twice independently using unrelated enzymes.